Pharmacokinetics and Pharmacodynamics of Intranasal Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Nose-to-Brain Delivery
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Nose-to-brain drug delivery has been of great interest for the treatment of many central nervous system (CNS) diseases and psychiatric disorders over past decades. Several nasally administered formulations have been developed to circumvent the blood-brain barrier and directly deliver drugs to the CNS through the olfactory and trigeminal pathways. However, the nasal mucosa’s drug absorption is insufficient and the volume of the nasal cavity is small, which, in combination, make nose-to-brain drug delivery challenging. These problems could be minimized using formulations based on solid lipid nanoparticles (SLNs) or nanostructured lipid carriers (NLCs), which are effective nose-to-brain drug delivery systems that improve drug bioavailability by increasing drug solubility and permeation, extending drug action, and reducing enzymatic degradation. Various research groups have reported in vivo pharmacokinetics and pharmacodynamics of SLNs and NLCs nose-to-brain delivery systems. This review was undertaken to provide an overview of these studies and highlight research performed on SLN and NLC-based formulations aimed at improving the treatment of CNS diseases such neurodegenerative diseases, epilepsy, and schizophrenia. We discuss the efficacies and brain targeting efficiencies of these formulations based on considerations of their pharmacokinetic parameters and toxicities, point out some gaps in current knowledge, and propose future developmental targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Intranasal delivery to the central nervous system: Mechanisms and experimental considerations
Dhuria, S. V., Hanson, L. R., & Frey, W. H. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21924 · Cited by 1,239
Nasal mucociliary clearance as a factor in nasal drug delivery
Marttin, E., Schipper, N. G. M., Verhoef, J. C., & Merkus, F. W. H. M. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00059-8 · Cited by 469
Gänger, S., & Schindowski, K. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030116 · Cited by 447
Surface-Modified Nanocarriers for Nose-To-Brain Delivery: From Bioadhesion to Targeting
Sonvico, F., Clementino, A. R., Buttini, F., Colombo, G., Pescina, S., Stanisçuaski Guterres, S., Raffin Pohlmann, A., & Nicoli, S. (2018) · doi:10.20944/preprints201802.0077.v1 · Cited by 306
Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies
Pires, P. C., & Santos, A. O. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.047 · Cited by 228
Evidence of nose-to-brain delivery of nanoemulsions: Cargoes but not vehicles
Ahmad, E., Feng, Y., Qi, J., Fan, W., Ma, Y., He, H., Xia, F., Dong, X., Zhao, W., Lu, Y., et al. (2017) · Nanoscale · doi:10.1039/c6nr07581a · Cited by 194
Pardeshi, C. V., Rajput, P. V., Belgamwar, V. S., Tekade, A. R., & Surana, S. J. (2013) · Drug Delivery · doi:10.3109/10717544.2012.752421 · Cited by 141
Gadhave, D., Rasal, N., Sonawane, R., Sekar, M., & Kokare, C. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.11.047 · Cited by 97
El-Zaafarany, G. M., Soliman, M. E., Mansour, S., & Awad, G. A. S. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.02.038 · Cited by 89
Cited by
Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs
Nunes, D., Loureiro, J. A., & Pereira, M. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112296 · Cited by 68
Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications
Taléns-Visconti, R., de Julián-Ortiz, J. V., Vila-Busó, O., Diez-Sales, O., & Nácher, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051399 · Cited by 59
Guo, H., Wang, G., Zhai, Z., Huang, J., Huang, Z., Zhou, Y., Xia, X., Yao, Z., Huang, Y., Zhao, Z., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.123809 · Cited by 31
Tanaka, M., Araujo, A. C., Valenti, V. E., Guiguer, E. L., Catharin, V. C. S., Gualhardi, C. M., de Souza Bastos Mazuqueli Pereira, E., de Alvares Goulart, R., de Argolo Haber, R. S., de Carvalho, A. C. A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052370 · Cited by 13
Surface modifications of nanoparticles and their suitability for studying gastrointestinal diseases
Obasi, C. C., & Banigo, A. T. (2026) · Nano-Bio-Medicine for Gastrointestinal Diseases · doi:10.1016/b978-0-443-34039-0.00010-x · Cited by 2
Metadata
- Authors
- Nguyen, T.-T.-L., & Maeng, H.-J.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-03-05
- Volume
- 14
- Issue
- 3
- Pages
- 572
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W4220949814
- Cited by
- 130
- References
- 10
- FWCI
- 8.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics and Pharmacodynamics of Intranasal Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Nose-to-Brain Delivery. https://app.cochat.ai/papers/10.3390/pharmaceutics14030572
- The paper
- Nguyen, T.-T.-L., & Maeng, H.-J. (2022). Pharmacokinetics and Pharmacodynamics of Intranasal Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Nose-to-Brain Delivery. Pharmaceutics. https://doi.org/10.3390/pharmaceutics14030572
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.